IL2 and cancer: Several studies demonstrated that, in addition to inhibiting T cell interleukin-2 (IL-2) production [50], proliferation [50] and tumor infiltration [49], PGE2 has also a major impact during the DC early stage development, inducing a shift towards an immunosuppressive activity [37,38], impairing DC differentiation, IL-12 production [36], DC function [37,38], promoting the development of tolerogenic DCs [38] and hence overall contributing to DC dysfunction in cancer [51].